Loading...

PODCAST

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week"s biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts,

science life sciences

All Episodes

00:06:50

Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/12

Vertex clears Phase 3 in kidney disease as after-hoursshares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence.#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Vertex, #kidney disease, #Eli Lilly, #China manufacturing, #GLP-1, #UCB, #Bimzelx,

en-us

00:06:54

Mar 10, 2026 | BioNTech's co-founders just walked away

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/11

BioNTech's co-founders just walked away. Both of them. Sameday. They're starting a new mRNA company from scratch. And the FDA approved a drug today without running a clinical trial. That's not a typo — we'll explain the precedent. #pharma, pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Pfizer, #Lilly, #Novo Nordisk, #Roche, #GSK, #VertexTags

en-us

00:07:01

Mar 09, 2026 | Novo Nordisk Partners with Hims on...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/10

Novo Nordisk and Hims end legal battle, team up for branded GLP-1 telehealth distribution. BMS gets Sotyktu psoriatic arthritis approval and Phase 3 CELMoD win. Incyte receives CRL due to Novo's Indiana manufacturingissues — third company hit by same facility.#pharma,# pharmaceutical, #FDA, #clinical trials, #biotech, #drug approvals, #healthcare, #pharma podcast, #The Pharma Closeout, #Novo Nordisk, #Hims& Hers, #GLP-1, #semaglutide, #Ozempic, #Wegovy, #obesity, #telehealth, #Bristol Myers

en-us

00:16:21

The AI Reckoning — Episode 3: The Agentic Enterprise

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/09

Agentic AI is moving from augmenting human work to acting autonomously — monitoring supply chains, adjusting production parameters, generating medical information responses. The EBITDA projections are enormous. So are the risks when an AI agent touches patients. We walk through the deployments, the economics, and the governance gap.#pharma, #agentic AI, #commercial operations, #manufacturing, #digital twins, #supply chain, #EBITDA, #governance, #EU AI Act, #Novo Nordisk, #GSK, #Pfizer

en-us

00:10:58

Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/09

This week, the pharma industry stacked three of the year's biggest deals in five days — and the FDA quietly told us something important about what happens when gene therapy evidence packages get thin. Meanwhile, the GLP-1 wars got more expensive for everyone not named Novo or Lilly. Let's take it apart.

en-us

00:12:13

Mar 06, 2026 | FDA not convinced AMT-130 works;...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/07

The FDA told uniQure it is not convinced AMT-130provides any therapeutic benefit in Huntington’s disease — the program now faces a full Phase Three, raising the evidentiary floor for all CNS gene therapy. Moderna jumped fourteen percent on forty-nine percent melanomarecurrence reduction from mRNA-4157 plus Keytruda, combined with resolution of its LNP patent overhang. Servier acquires Day One Biopharmaceuticals fortwo-and-a-half billion dollars; Zealand’s petrelintide obesity data triggers a

en-us

00:12:19

Mar 5, 2026 | Theravance Phase 3 CYPRESS Failure...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/06

Theravance Biopharma’s Phase 3 CYPRESS trial of ampreloxetine in neurogenic orthostatic hypotension fails to meet the primary OHSA endpoint at week 8. The company announces a 50% workforce reduction, shuts down R&D, and targets 60% cash burn reduction ($70M annual savings) as it pivots to Yupelri (revefenacin) as its sole commercial asset. Stock drops 26% from $18.95 to $13.96. Science Corporation closes a $230 million Series C at a $1.5 billion valuation for its PRIMA retinal brain-computer

en-us

00:12:02

Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement,...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/06

Moderna agrees to pay up to $2.25 billion to settle the lipid nanoparticle patent dispute with GenevantSciences and Arbutus Biopharma — $950M upfront in July 2026, with $1.3B contingent on a government contractor immunity appeal under Section 1498. The settlement grants Moderna a global non-exclusive LNP license for infectious disease applications. FDA issues 30 warning letters to telehealth companies overcompounded GLP-1 marketing, its most aggressive enforcement action yet as the shortage-era

en-us

00:19:15

Special Series| AI Reckoning Ep 2: From Molecule to...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/05

173 AI-discovered drugs in clinical development. Phase 1 success rates of 80-90% vs 52% traditional. But at Phase 2, the AI advantage disappears — and nobody's talking about it. We unpack rentosertib's Nature Medicine data, zasocitinib's Phase 3 win, the Recursion pipeline reality, synthetic control arms cutting trial timelines by18 months, the FDA's 7-step AI credibility framework, and what this means for R&D careers. Episode 2 of "The AI Reckoning: Pharma's

en-us

00:12:02

Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/03

Novo Nordisk commits €432 million ($506M) to expand oral semaglutide tablet manufacturing in Athlone,Ireland — a supply bet on oral Wegovy’s trajectory as 246,000 patients are already on therapy. Morgan Stanley upgrades Novo from Underweight to Equal Weight,citing ~56% potential upside as a floor call, while Lilly holds a 21-point GLP-1 market share lead (60.5% vs 39.1%). Orforglipron’s Q2 FDA decision is the next test of whether Novo can hold the oral lane. BMS has a PDUFA on Friday for Sotyktu’s

en-us

00:10:18

Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/03

Gilead acquires Arcellx for $7.8B to challenge J&J’s Carvykti in multiple myeloma with a December FDAdecision approaching. Both Friday decisions resolved: YUVIWEL wins accelerated approval as the first weekly achondroplasia treatment, Dupixent adds AFRS toits ENT franchise. PADCEV plus Keytruda delivers a 47% recurrence reduction in muscle-invasive bladder cancer. CagriSema analyst downgrades continue, and theMarch 20th Rhythm decision could reshape the obesity landscape.

en-us

00:17:38

Mar 1, 2026 | CagriSema Week of Reckoning: Analysts...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/03

Seven analyst downgrades, Deutsche Bank at Hold with a 275 DKK target, Morningstar cutting CagriSema peaksales from $13B to $8B. We cover the open-label design limitation constraining Novo's patient-reported outcome claims and where the differentiation argumenthas to go next. Plus GSK's $950M activin bet, China licensing at record pace, Lilly's ACHIEVE-3 win. FDA approved YUVIWEL with a $100–150M PRV. Dupixent'sninth indication. Pfizer/Astellas bladder cancer data that deserved more

en-us

00:10:02

Feb 27, 2026 | CagriSema's New Story After REDEFINE...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/03

Novo's CagriSema misses non-inferiority against Zepbound in REDEFINE 4 — approval path intact,differentiation argument shifts to outcomes data. GSK pays $950M for HS235 (35Pharma), a Phase 1 activin inhibitor targeting Merck's Winrevair territory.Lilly's ACHIEVE-3 puts orforglipron decisively ahead of oral semaglutide: 31.4% of patients to near-normal A1C vs 11.7%. Two FDA decisions today: TransCon CNP for achondroplasia and Dupixent's AFRS label expansion.

en-us

00:18:13

Special Series| AI Reckoning Ep 1: The Reckoning — 5%...

The Pharma Closeout | Daily Pharmaceutical and... ·

2026/03/02

Only 5% of pharma companies have turned AI into competitive advantage. 89% of AI pilots fail to scale. The gap is widening, not closing. We unpack the $6.6B market reality, what "production scale" actually means vs. what companies claim, why 80% of AI transformation is organizational change not technology, the skills half-life crisis (2-5 years by 2030), and the board governance vacuum. Episode 1 of our 4-part special series "The AI Reckoning: Pharma's Make-or-Break

en-us

174 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Short Science Fiction Collection

Vaqrious

Planetterrian Daily

Patrick · Nerra Network

Short Wave

NPR

La Science CQFD

France Culture